Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Summary

This study is a Phase 1, open-label, dose escalation and cohort expansion trial designed to characterize the safety, tolerability, PK, PD, immunogenicity and preliminary antitumor activity of enoblituzumab administered IV on a weekly schedule for up to 96 doses (approximately 2 years) in children and young adults with B7-H3-expressing relapsed or refractory malignant solid tumors.

Timeline

Start

2016-12

Primary completion

2019-05-22

Completion

2019-05-22

Drugs

Indications